Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 1,840 shares, a growth of 589.1% from the September 15th total of 267 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average trading volume of 21,028 shares, the short-interest ratio is currently 0.1 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Addex Therapeutics presently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on Addex Therapeutics
Addex Therapeutics Trading Down 2.2%
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last released its quarterly earnings data on Friday, September 25th. The company reported ($1.48) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter.
About Addex Therapeutics
Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. Founded in 2002, the company develops small-molecule medicines designed to treat neurological disorders by modulating G protein-coupled receptors through allosteric mechanisms.
The company’s research and development programs have focused on conditions affecting the central nervous system. Its pipeline has included dipraglurant, an investigational negative allosteric modulator of the metabotropic glutamate 5 receptor being studied for neurological disorders including Parkinson’s disease levodopa-induced dyskinesia, as well as other investigational compounds targeting glutamate receptors for conditions such as schizophrenia and migraine.
Addex conducts its drug discovery and clinical development activities internationally, with research centered in Switzerland and clinical and commercial development intended for global markets.
See Also
- Five stocks we like better than Addex Therapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
